ACT DMD Update with PTC (February 2014) On February 5, 2014, Dr. Robert Spiegel, Chief Medical Officer at PTC Therapeutics, presented an update about PTC’s Phase 3 study of ataluren, now known as the Ataluren Confirmatory Trial in DMD (ACT DMD). Research & Clinical Trial Webinars,Webinars 11 years ago You may also like 43:40 Webinar: Interim Results from FORWARD-53 Study of WVE-N531 in Duchenne Muscular Dystrophy 8 months ago Research & Clinical Trial Webinars,Webinars wave life sciences,WVE-N531 51:42 Webinar: Overview of DUVYZAT and Access Resources (September 2024) 9 months ago Research & Clinical Trial Webinars,Webinars 1:04:54 Webinar: Advocating for A Successful School Year (September 2024) 9 months ago Care Webinars,Webinars 1:01:24 Webinar: PPMD Advocacy – Raising Our Voices in 2024 and Beyond [Sep 2024] 9 months ago Webinars 1:00:59 Webinar: Advancing DYNE-251 – An Investigational Medicine for Duchenne to Deliver for Patients 10 months ago Research & Clinical Trial Webinars,Webinars dyne therapeutics,DYNE-251 1:05:32 Webinar: Edgewise Therapeutics – Clinical Trials in Becker Muscular Dystrophy 10 months ago Research & Clinical Trial Webinars,Webinars edgewise 58:10 Webinar: Community Progress in Duchenne Newborn Screening 1 year ago Webinars feature,newborn screening 1:01:30 Webinar: Community Update with ITF Therapeutics – Introducing DUVYZAT™ (givinostat) 1 year ago Research & Clinical Trial Webinars,Webinars duvyzat,feature,givinostat,itf therapeutics «12345…26»Page 3 of 26